Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoBio has released results from recent animal studies evaluating NanoStat-based intranasal respiratory syncytial virus (RSV) vaccine.
Subscribe to our email newsletter
The results of the studies showed that the company’s RSV vaccine induces protective immunity in mice without eliciting the enhanced respiratory disease that has caused other RSV vaccine candidates to fail.
NanoBio Vaccine Research and Development senior vice president Ali Fattom said in these studies, they observed the NanoStat-based RSV vaccine to induce robust immunity while decreasing mucus production and increasing viral clearance without Th2-mediated immune potentiation," Fattom said.
"These attributes have not been seen with prior vaccine candidates, and indicate significant potential for the development of the first safe and effective RSV vaccine."